Role of Interleukin-13 Pathways on Pain and Itch Sensitivity

Launched by AALBORG UNIVERSITY · Jul 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of a specific protein called IL-13 in causing itch and pain, especially in people with a skin condition known as atopic dermatitis (AD). Atopic dermatitis is a long-lasting skin problem that affects many people around the world, causing intense itching and discomfort. The trial is looking at how a medication called Lebrikizumab, which blocks IL-13, can help understand and possibly reduce these symptoms in both healthy participants and those with AD.

To participate in this trial, individuals must be healthy men or women between the ages of 18 and 60. However, certain people cannot join, including those who are pregnant or breastfeeding, those with a history of specific health conditions, or those currently using certain medications like pain relievers or allergy medicines. Participants can expect to undergo tests to see how IL-13 affects their itch and pain responses. It’s important to note that the trial is currently active but not recruiting new participants, meaning they are not looking for additional volunteers at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy men and women
• • 18-60 years
• Exclusion Criteria:
• • Pregnancy or lactation
• • Drug addiction defined as any use of cannabis, opioids, or other drugs
• • Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
• • Moles, wounds, scars, or tattoos in the area to be treated or tested
• • Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
• • Use of systemic and topical corticosteroids
• • Consumption of alcohol or painkillers 24 hours before the study days and between these
• • Acute or chronic pain
• • Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
• • Lack of ability to cooperate